Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-CD37/ANTI-CD3 BISPECIFIC ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2023/219120
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing an anti-CD37/anti-CD3 bispecific antibody that can be used in treatment of humans.　The present inventors created multiple anti-CD3scFvs having improved stability and varying affinities for CD3 and created multiple anti-CD37/anti-CD3 bispecific antibodies using the same. Many of the bispecific antibodies exhibited undesirable properties at high concentrations, such as in vitro cytotoxicity and weakening of cytokine production activity. Antibodies discovered by a series of studies not to weaken in activity even at high concentration exhibited an antitumor action in vivo. Therefore, these antibodies can be used to treat human cancers that express CD37.

More Like This:
JP2023015277CXCR4 BINDING MOLECULES
JP2022505585ALK2 antibody and how to use it
JP2021508709Anti-renalase antibodies for the treatment and prevention of diseases and disorders
Inventors:
SOGA SHINJI (JP)
YAGI SHIGENORI (JP)
HONDA TAKASHI (JP)
Application Number:
PCT/JP2023/017658
Publication Date:
November 16, 2023
Filing Date:
May 11, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ASTELLAS PHARMA INC (JP)
International Classes:
C12N15/13; A61K39/395; A61P35/00; A61P35/02; C07K16/28; C07K16/32; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/12; C12N15/62; C12N15/63; C12P21/02
Domestic Patent References:
WO2014151438A12014-09-25
WO2020225805A22020-11-12
WO2015017552A12015-02-05
WO2022102768A12022-05-19
WO2022224997A12022-10-27
Foreign References:
JP2009511521A2009-03-19
US20190016823A12019-01-17
Attorney, Agent or Firm:
YAMAMOTO, Osamu et al. (JP)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: METHOD FOR PRODUCING EXTRACELLULAR VESICLES CONTAINING BIOACTIVE SUBSTANCE

Next Patent: ANTI-TAA/ANTI-CD3 MULTISPECIFIC ANTIBODY